Host cell virus entry mechanisms enhance anti-JCV-antibody switch in natalizumab-treated multiple sclerosis patients. Achiron A, Miron G, Zilkha-Falb R, Magalashvili D, Dolev M, Stern Y, Gurevich M J Neurovirol. 2016 May 11. PMID: 27170332. Abstract CommentRecommendBookmarkWatch